Bis-choline tetrathiomolybdate is in clinical development for the treatment of Wilson’s disease (WD). WD is a genetic disorder that prevents the body from removing extra copper, causing copper to build up in the liver, brain, eyes, and other organs. The copper overload in WD is either treated with chelators or zinc. Despite current therapies, there are several situations in which current medications cannot avoid an unsatisfactory outcome. Bis-choline tetrathiomolybdate, through oral administration, is expected to rapidly attach to copper and to a protein called albumin in the bloodstream. This prevents copper to be taken up by the organs and is eliminates it from the body. Therefore, the damaging effects of copper are expected to be reduced. In comparison to current treatments, bis-choline tetrathiomolybdate provides an alternative copper-protein binding mechanism. If licenced, bis-choline tetrathiomolybdate will offer an additional treatment option for WD patients.